ArticleJournal of molecular histology2026
Pirfenidone attenuates urethral stricture after injury by inhibiting Gli2 mediated HAS2 expression in fibroblasts.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Activation of fibroblasts and excessive deposition of extracellular matrix are the primary causes of urethral stricture following injury. Pirfenidone (PFD) is an established antifibrotic drug approved for the treatment of idiopathic pulmonary fibrosis, however, its potential role in preventing urethral stricture remains unclear. In this study, we investigated the effects of PFD on urethral stricture after injury and explored the underlying mechanisms both in vivo and in vitro. Our results demonstrated that PFD effectively attenuated urethral stricture and fibrosis in mice and suppressed fibroblast proliferation, migration, and invasion while promoting apoptosis. Mechanistically, RNA sequencing revealed that PFD significantly inhibited the expression of hyaluronan synthase 2 (HAS2), a key regulator of fibroblast activity. In addition, PFD suppressed GLI family zinc finger 2 (Gli2) expression in a Sonic hedgehog (Shh)–independent manner, which mediated the regulation of HAS2 by PFD. Furthermore, we found that Gli2 reduced HAS2 expression through the TGF-β1/Smad signaling pathway. Collectively, these findings indicate that PFD may serve as a promising therapeutic candidate for the prevention and treatment of urethral stricture.
Indexed as
Identifiers
41758306What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.